Zimmer Biomet, a specialist in medical technology and orthopedics, announced raising its revenue growth forecasts for 2026 to range between 4.4% and 4.9%, despite recording lower-than-expected results in knee implant sales during the third quarter.
Mixed Performance and Commercial Challenges
The company recorded sales in the knee segment amounting to $767.5 million, representing a 3.1% year-on-year decrease. In contrast, the hip implant segment saw 6% growth, reaching $536.5 million. The company's CEO, Evan Turner, rejected the hypothesis of a general slowdown in the medical technology market, considering that the performance in the knee segment is due to challenges in commercial execution, specifically the transition toward a fully dedicated sales team, in addition to intense competition in this sector.
What Does This Mean for Investors and the Market?
This divergence in analysis comes after competitor Stryker attributed its weak sales last week to challenges related to affordability and health insurance, which raised questions among analysts about the state of the orthopedic surgery market. However, Turner believes that surgical procedures in ambulatory surgery centers are in continuous growth, and that pricing and cancellation rates remain stable, reinforcing the company's confidence in its financial goals.
Development of Surgical Robotics
On the technical innovation front, Zimmer Biomet plans to submit an application to the Food and Drug Administration (FDA) for approval of a new surgical robot, following its acquisition of Monogram Technologies. The company expects to launch a completely autonomous version of this robot in the first half of 2027. According to Turner, this system represents a strategic incentive to attract surgeons who do not currently use robotics, as clinical trials have shown high efficiency and ease of use, along with tangible improvements in surgical precision.